AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620
Category: #health  By Mateen Dalal  Date: 2019-09-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620

As cases of neurodegenerative diseases like Alzheimer’s and Parkinson’s are on a rise, biopharmaceutical firms are actively engaging in developing new clinical drugs. Companies are also gaining increased funding from partners to further their cause in this field.

AC Immune SA, a clinical-stage biopharmaceutical company that develops a novel treatment for neurodegenerative diseases, recently gained a milestone payment from partner Life Molecular Imaging to commence the Phase 2 trial of Tau PET (positron-emission tomography) tracer PI-2620.

According to reports, PI-2620 is developed using the firm’s patented Morphomer™ discovery platform in a joint venture with Life Molecular Imaging GmbH, a diagnostic imaging and molecular solutions provider.

The drug plays an important role in quantifying and detecting early Tau deposition in the brain. It also displays potential for non-AD Tauopathies like PSP (progressive supranuclear palsy).

Speaking on the move, Prof. Andrea Pfeifer, CEO, AC Immune, said that the clinical development of PI-2620 is built on its superior imaging and properties characteristics, further bolstering the ability of the company’s Morphomer™ technology and its capability to form lucrative partnerships with established companies like Life Molecular Imaging.

Reportedly, in 2014, Life Molecular Imaging and AC Immune entered into a global license deal for commercialization, development and research of AC Immune's Tau PET tracers supporting the diagnosis of potential Tau-related disorders.

In addition to the recent move, the biopharmaceutical firm was earlier awarded a new grant for its groundbreaking alpha-synuclein (a-syn) PET (positron-emission tomography) tracer program by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Moreover, over the past four years, the company has received constant grant support from the foundation to advance the study of a-syn PET tracers which, if successful, could offer the world’s first imaging agent competent enough to precisely monitor and detect the progression of PD (Parkinson’s disease).

Source Credit: https://ir.acimmune.com/news-releases/news-release-details/ac-immune-receives-milestone-payment-connection-initiation-phase?field_nir_news_date_value%5bmin%5d=2019

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
By Mateen Dalal

Hyundai Motor Company identifies the significance and impact of automobiles, and strives to fulfill its goals by creating new and advanced vehicles that addresses all the vital issues faced by drivers. The automobile giant has effectively become...

TransPerfect expands its portfolio by acquiring Sublime Subtitling
TransPerfect expands its portfolio by acquiring Sublime Subtitling
By Mateen Dalal

With decades of hard work and hands-on experience, TransPerfect has managed to become one of the largest global providers of technology and language solutions for companies worldwide. With over 5,000 global organizations employing its GlobalLink®...

Altran to launch a Digital Therapeutics Innovation Center in Boston
Altran to launch a Digital Therapeutics Innovation Center in Boston
By Mateen Dalal

Digital therapeutics are evidence-based interventions conducted by advanced software programs to manage, treat or prevent clinical disorders. Its adoption has augmented the whole medical industry, making it simpler for practitioner to ...